Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0530 in Advanced Gastric Carcinoma
NCT00607594Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of saracatinib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Primary endpoints: Objective Tumor Response at 37 weeks and Prolonged Stable Disease Rate at 37 weeks. Started Jan 2008; status: completed.
02
Drugs
saracatinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00607594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00607594.